Can Ashwagandha Cause High AST? What the Evidence Says About Liver Safety
Automated draft updated
Ashwagandha can, in rare cases, cause elevated AST (aspartate aminotransferase) and other liver enzymes, consistent with drug-induced or herb-induced liver injury (DILI/HILI). The risk appears low in the general population using standardised extracts at recommended doses, but case reports confirm a real — if uncommon — hepatotoxic signal that warrants attention.
What Is AST and Why Does It Matter?
AST is an enzyme found primarily in liver cells. When liver cells are damaged or inflamed, AST leaks into the bloodstream, causing elevated serum levels. Clinicians use AST alongside ALT (alanine aminotransferase) and bilirubin to assess liver health. A sustained or sharply elevated AST signals that something — a drug, herb, toxin, or disease — may be injuring hepatocytes. Monitoring AST is therefore a standard safety checkpoint when evaluating herbal supplement use.
How Might Ashwagandha Affect the Liver?
The precise mechanism by which ashwagandha may elevate AST is not fully established, but several hypotheses exist:
- Withanolide accumulation: The bioactive steroidal lactones (withanolides) in ashwagandha are metabolised hepatically. High-concentration extracts — such as those standardised to 35% withanolides like Shoden — deliver substantially more withanolides per dose than traditional preparations, potentially stressing cytochrome P450 pathways.
- Idiosyncratic immune reaction: Some DILI cases appear immune-mediated, occurring even at standard doses in genetically susceptible individuals, rather than following a predictable dose-response curve.
- Contaminant load: Poorly manufactured or unadulterated products may contain heavy metals or microbial toxins that independently stress the liver. This makes product quality a critical variable.
- Cholestatic pattern: Several published case reports describe a cholestatic-hepatocellular pattern, where bile flow is impaired alongside direct hepatocyte injury, leading to elevated AST, ALT, alkaline phosphatase, and bilirubin.
What Does the Clinical Evidence Show?
As of current literature, there are roughly a dozen peer-reviewed case reports linking ashwagandha supplementation to clinically meaningful liver enzyme elevation, including high AST. Most cases resolved within weeks to months after discontinuation (a pattern called "RUCAM-positive dechallenge"), supporting causality.
Controlled trials using standardised extracts such as KSM-66 and Sensoril — both of which use the root or combined root-and-leaf — have not systematically reported AST elevations at label-recommended doses (typically 300–600 mg/day). However, these trials were not powered or designed to detect rare hepatic adverse events affecting fewer than 1 in 1,000 users.
Higher-withanolide preparations require particular caution. Shoden ashwagandha, standardised to 35% withanolides, delivers a withanolide dose far above traditional use and has the least long-term safety data of the major proprietary extracts.
Dosage and Risk Factors
Risk appears to increase with:
- Higher doses (above 1,000 mg/day of concentrated extract)
- Longer duration of unmonitored use
- Concurrent hepatotoxic medications (statins, acetaminophen, alcohol)
- Pre-existing liver disease or elevated baseline liver enzymes
- Use of unregulated or non-standardised products such as wild ashwagandha or homemade preparations without potency verification
For most healthy adults, 300–600 mg/day of a root-only extract like KSM-66 for 8–12 weeks, with periodic liver function monitoring, is considered an evidence-aligned approach.
Practical Safety Guidance
- Baseline testing: If you have any liver history or take hepatically-metabolised medications, obtain an AST/ALT panel before starting.
- Choose standardised extracts: Proprietary root extracts with published safety data carry a more defined risk profile than uncharacterised powders.
- Monitor during use: A repeat liver panel at 6–8 weeks catches early enzyme changes before they progress.
- Stop if symptoms appear: Jaundice, dark urine, right-upper-quadrant discomfort, or significant fatigue warrant immediate cessation and medical evaluation.
- Avoid stacking hepatotoxins: Do not combine ashwagandha with alcohol, kava, or high-dose niacin without medical supervision.
---
Related Topics
Frequently asked questions
How common is ashwagandha-induced AST elevation?
Clinically significant liver enzyme elevation from ashwagandha appears rare, estimated at well under 1% based on case report frequency relative to global usage. However, because most supplement users never get liver panels, the true incidence may be underreported. Individuals with liver risk factors should monitor more closely.
Which ashwagandha form is safest for liver health?
Root-only extracts such as KSM-66, standardised to around 5% withanolides, have the most clinical safety data and have not produced systematic AST signals in trials. Leaf-containing extracts and ultra-high withanolide preparations like Shoden (35% withanolides) carry less long-term hepatic safety data and should be used more cautiously.
How long does it take for AST to normalize after stopping ashwagandha?
In published case reports, liver enzymes typically returned to normal within 4–12 weeks of discontinuing ashwagandha, provided no underlying liver disease was present. Recovery was generally faster in cases detected early. Continuing use after noticing elevated enzymes prolongs injury and may worsen outcomes.
Should I get a liver test before taking ashwagandha?
A baseline AST/ALT panel is advisable for anyone with prior liver disease, alcohol use, or who takes hepatically-metabolised medications. For healthy adults with no risk factors, baseline testing is optional but provides useful reference data. A follow-up panel at 6–8 weeks of use offers an additional safety check.